World Health Organization site
Skip Navigation Links

Main
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.
Register: ISRCTN
Last refreshed on: 5 January 2021
Main ID:  ISRCTN89237105
Date of registration: 14/08/2014
Prospective Registration: No
Primary sponsor: Scientific Institute for Quality of Healthcare (IQ healthcare) (Netherlands)
Public title: Improving participation rates by providing choice on participation mode
Scientific title: Improving participation rates by providing choice on participation mode: Randomized controlled trials.
Date of first enrolment: 01/06/2013
Target sample size: 338
Recruitment status: Completed
URL:  http://isrctn.com/ISRCTN89237105
Study type:  Interventional
Study design:  Randomized controlled trial (Quality of life)  
Phase:  Not Applicable
Countries of recruitment
Netherlands
Contacts
Name: Michel    Wensing
Address:  Geert Grooteplein 21 6525 EZ Nijmegen Netherlands
Telephone:
Email:
Affiliation: 
Name:    
Address: 
Telephone:
Email:
Affiliation: 
Key inclusion & exclusion criteria
Inclusion criteria:
1. Patients with high risk for CVD and established CVD
2. Adults aged 18 or older and who are capable of providing informed consent
3. Patients with high risk for CVD have a risk score of 20% or higher on 10-years-morbidity and mortality due to CVD
International Classifications of Primary care (ICPC) codes were used to extract eligible patients from medical records from general practices.

Exclusion criteria:
1. Diabetes mellitus
2. Pregnancy and lactation
3. Terminal illness
4. Cognitive impairments
5. Poor language skills


Age minimum:
Age maximum:
Gender: Both
Health Condition(s) or Problem(s) studied
Patients at high risk for cardiovascular disease and with established cardiovascular disease.
Circulatory System
Intervention(s)

This study is part of the ?Tailored Implementation for Chronic Diseases? (TICD) project and is integrated in a program evaluation which has been designed as a two arm randomized controlled trial (NTR4069). For purposes of the program evaluation, patients received a questionnaire booklet containing mainly questions on health-related lifestyle. For purposes of the randomized controlled trials of participation rates, different invitations were included at the last page of the questionnaire booklet to invite patients for participation in a social network study on health-related information sharing. For determining whether providing choice on participation mode improved participation rates, patients were randomly allocated to receive one of two formats of invitations. On the choice format invitations, patients could indicate whether they wanted to participate in the network study by:
1. A telephone interview or
2. A postal questionnaire.
On the single format invitation, only one participation mode was offered. Invitations were varied over two trials.
Trial 1: Participation rates are compared of patients who received a choice format invitation with that of patients who received a single format invitation to participate by a telephone interview.
Trial 2: Participation rates are compared of patients who received the choice format invitations with that of patients who received a single format invitation to participate by a postal questionnaire.
Primary Outcome(s)
Participation rate, defined as the percentage of patients who actually participated in the social networks study. That is the total number of patients who had completed an interview or questionnaire for the social networks study divided by the total number of participants in the program evaluation.
Secondary Outcome(s)

1. Conditional participation rate: Defined as the total number of patients who had completed an interview or questionnaire for the social networks study divided by the total number of patients willing to participate in the study.
2. Willingness to participate: Defined as the percentage of patients initially willing to participate in the social network study. That is the total number of patients willing to participate divided by the number of participants in the program evaluation.

The response trials are embedded within a program evaluation which has been designed as a two-arm randomized controlled trial. For this program evaluation, questionnaires containing invitations for the response trials were send at baseline of the program. Willingness to participate and preference for participation mode, were measured up to 2 months after sending questionnaires with invitations. We planned to perform interviews and send questionnaires on behalf of the social networks study within two months after receipt of completed invitations.
Secondary ID(s)
N/A
Source(s) of Monetary Support
European Union Seventh Framework Programme (FP7) within the theme HEALTH.2013.3.1-1 under grant agreement no 258837 (Belgium), ZonMw (The Netherlands Organisation for Health Research and Development) project no 200310011.(Netherlands)
Secondary Sponsor(s)
Ethics review
Status:
Approval date:
Contact:
Ethics approval not required. The study protocol and its materials (e.g. questionnaires and letters) were submitted to the Medical Ethical Committee of Radboud University Medical Centre Nijmegen. This committee assessed that the Dutch law for medical scientific research does not apply to this research. As the research does not involve testing of body materials, it was decided that no approval was required from a local medical ethical committee as well.
Results
Results available: Yes
Date Posted:
Date Completed: 31/03/2014
URL:
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.6 - Version history